FDA approval summary: in 266 patients with FGFR3-altered advanced urothelial carcinoma after prior therapy, erdafitinib improved median OS vs docetaxel or vinflunine (12.1 vs 7.8 months; HR 0.64). No OS benefit vs pembrolizumab (HR 1.18), so use is limited.
RCTn = 266
Maguire et al. FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma